Verrica Pharmaceuticals reported a quarterly loss of $0.41 per share, beating the Zacks Consensus Estimate for a $0.59 loss by $0.18 per share. The result also improved from a $1.00 per-share loss in the prior-year period, indicating year-over-year earnings progress. The print is modestly positive for the stock, though still reflects ongoing unprofitability.
Verrica Pharmaceuticals reported a quarterly loss of $0.41 per share, beating the Zacks Consensus Estimate for a $0.59 loss by $0.18 per share. The result also improved from a $1.00 per-share loss in the prior-year period, indicating year-over-year earnings progress. The print is modestly positive for the stock, though still reflects ongoing unprofitability.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
